Since the receptor complexes for IFN-I and IFN-γ both signal via the JAK-STAT pathway, simultaneous inhibition of these pathways may help explain the therapeutic effects of JAK inhibitors, which are increasingly used for the treatment of HLH and MAS (37). This evidence concerns the gene SOAT1 and hemophagocytic syndrome.